Lu‐En Wai

639 total citations
13 papers, 190 citations indexed

About

Lu‐En Wai is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Lu‐En Wai has authored 13 papers receiving a total of 190 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Immunology and 6 papers in Epidemiology. Recurrent topics in Lu‐En Wai's work include CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (4 papers). Lu‐En Wai is often cited by papers focused on CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (4 papers). Lu‐En Wai collaborates with scholars based in Singapore, China and United States. Lu‐En Wai's co-authors include Olivia M. Martinez, Sheri M. Krams, Masato Fujiki, Jordan Garcia, Sarene Koh, Antonio Bertoletti, Mouer Wang, Ming Zhuo, Anthony T. Tan and Wenjie Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Hepatology.

In The Last Decade

Lu‐En Wai

11 papers receiving 185 citations

Peers

Lu‐En Wai
Jessica Voss United States
Sarah Thirkell United Kingdom
Anupriya S. Kulkarni United States
Adam Kornberg United States
Werner Frings United States
Yamila Rocca Argentina
Amir Ferry United States
Saif Lalani United States
Jessica Voss United States
Lu‐En Wai
Citations per year, relative to Lu‐En Wai Lu‐En Wai (= 1×) peers Jessica Voss

Countries citing papers authored by Lu‐En Wai

Since Specialization
Citations

This map shows the geographic impact of Lu‐En Wai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu‐En Wai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu‐En Wai more than expected).

Fields of papers citing papers by Lu‐En Wai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu‐En Wai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu‐En Wai. The network helps show where Lu‐En Wai may publish in the future.

Co-authorship network of co-authors of Lu‐En Wai

This figure shows the co-authorship network connecting the top 25 collaborators of Lu‐En Wai. A scholar is included among the top collaborators of Lu‐En Wai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu‐En Wai. Lu‐En Wai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
2.
Tan, Anthony T., Adeline Chia, Nicole Tan, et al.. (2025). THU-081 Association of Tcell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC. Journal of Hepatology. 82. S433–S433. 1 indexed citations
3.
Tan, Anthony T., Nicole Tan, Thinesh Lee Krishnamoorthy, et al.. (2024). A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells. PubMed. 4(1). ltae007–ltae007.
5.
Chen, Qi, Adeline Chia, Yanchun Peng, et al.. (2023). Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy. Cellular and Molecular Immunology. 20(11). 1300–1312. 2 indexed citations
6.
Lin, Meiyin, S Bhakdi, Damien Tan, et al.. (2023). Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. PubMed. 3(1). ltad015–ltad015. 2 indexed citations
7.
Chen, Wenjie, Jintao Cheng, Xiaofang Zheng, et al.. (2020). 273 Phase i study of LioCyx-M, autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, in recurrent HBV-related hepatocellular carcinoma (HCC) post-liver transplantation. SHILAP Revista de lepidopterología. A167.1–A167. 4 indexed citations
8.
Hafezi, Morteza, Meiyin Lin, Adeline Chia, et al.. (2020). Immunosuppressive Drug‐Resistant Armored T‐Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. Hepatology. 74(1). 200–213. 38 indexed citations
9.
Wai, Lu‐En, et al.. (2013). In silico modeling of cancer cell dissemination and metastasis. Annals of the New York Academy of Sciences. 1284(1). 71–74. 1 indexed citations
10.
Toh, Benjamin, Valerie Chew, Xilei Dai, et al.. (2012). Immune predictors of cancer progression. Immunologic Research. 53(1-3). 229–234. 8 indexed citations
11.
Zhuo, Ming, Masato Fujiki, Mouer Wang, et al.. (2010). Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection. European Journal of Immunology. 40(6). 1748–1757. 22 indexed citations
12.
Wai, Lu‐En, Jordan Garcia, Olivia M. Martinez, & Sheri M. Krams. (2010). Distinct Roles for the NK Cell-Activating Receptors in Mediating Interactions with Dendritic Cells and Tumor Cells. The Journal of Immunology. 186(1). 222–229. 20 indexed citations
13.
Wai, Lu‐En, et al.. (2008). Rapamycin, But Not Cyclosporine or FK506, Alters Natural Killer Cell Function. Transplantation. 85(1). 145–149. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026